Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation

Sean SternEvidera, Bethesda, MD, USA; Correspondence[email protected]

Alexandra J. WardEvidera, Waltham, MA, USA;

Fernando CamachoDamos, North York, ON, Canada;

Elham RahmeMcGill University Health Centre, Montreal, QC, Canada;

Dominik NaessensJanssen Pharmaceutica, NV, Beerse, Belgium;

Guy AumaisCIUSS est de Montreal at Maisonneuve-Rosemont Hôpital, Montreal, QC, Canada; ;Université de Montréal, QC, Canada;

Edmond-Jean BernardUniversité de Montréal, QC, Canada; ;IBD Clinic, Hôtel-Dieu de Montreal CHUM, Montreal, QC, Canada;

Raymond BourdagesCISSS Chaudière-Apalaches at Hôtel-Dieu de Lévis, Lévis, QC, Canada; ;Université Laval, Québec City, QC, Canada;

Albert CohenDivision of Gastroenterology, Jewish General Hospital, Montreal, QC, Canada; ;McGill University, Montreal, QC, Canada;

Pierre PareUniversité Laval, Québec City, QC, Canada; ;CHU de Québec, Hôpital du Saint-Sacrement, Québec City, QC, Canada;

Peter DyrdaJanssen Inc., Toronto, ON, Canada

Your download is now in progress and you may close this window